MARKET

TNYA

TNYA

Tenaya Therapeutics, Inc.
NASDAQ
0.4139
-0.0267
-6.06%
After Hours: 0.4219 +0.008 +1.93% 19:14 05/09 EDT
OPEN
0.4500
PREV CLOSE
0.4406
HIGH
0.4500
LOW
0.3921
VOLUME
4.02M
TURNOVER
--
52 WEEK HIGH
4.890
52 WEEK LOW
0.3921
MARKET CAP
67.33M
P/E (TTM)
-0.3159
1D
5D
1M
3M
1Y
5Y
1D
Strong Buy Recommendation for Tenaya Therapeutics Amid Promising Trial Results and Financial Stability
TipRanks · 11h ago
Tenaya Therapeutics Is Maintained at Buy by Chardan Capital
Dow Jones · 20h ago
Analysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL), Stevanato Group (STVN) and Tenaya Therapeutics (TNYA)
TipRanks · 1d ago
Promising Advancements and Stable Financials: A Buy Rating for Tenaya Therapeutics
TipRanks · 1d ago
Tenaya Therapeutics Reports Q1 2025 Financial Results
TipRanks · 2d ago
Buy Rating for Tenaya Therapeutics Driven by Promising Clinical Developments and Strategic Restructuring
TipRanks · 2d ago
Tenaya Therapeutics GAAP EPS of -$0.24
Seeking Alpha · 2d ago
BRIEF-Tenaya Therapeutics Q1 Net Income USD -26.864 Million
Reuters · 2d ago
More
About TNYA
More
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.
Recently
Symbol
Price
%Change

Webull offers Tenaya Therapeutics Inc stock information, including NASDAQ: TNYA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TNYA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TNYA stock methods without spending real money on the virtual paper trading platform.